.

Pharmaceutical Business Intelligence

  • Anticipate P&T budget requirements
  • Evaluate market entry opportunities
  • Find generic sources and suppliers
  • Predict branded drug patent expiration

► Plans and Pricing

Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

DrugPatentWatch Database Preview

Claims for Patent: 4,521,431

« Back to Dashboard

Claims for Patent: 4,521,431

Title: Aminoalkyl furan derivative
Abstract:A novel crystal form of ranitidine (N-[2-[[[5-(dimethylamino)methyl]-2-furanyl]methyl]thio]ethyl-N'-methyl-2- nitro-1,1-ethenediamine) hydrochloride, designated Form 2, and having favorable filtration and drying characteristics, is characterized by its infra-red spectrum and/or by its x-ray powder diffraction patterns.
Inventor(s): Crookes; Derek L. (Hertford, GB2)
Assignee: Glaxo Group Limited (London, GB2)
Application Number:06/406,710
Patent Claims: 1. Form 2 ranitidine hydrochloride characterised by an infra-red spectrum as a mull in mineral oil showing the following main peaks:

2. Form 2 ranitidine hydrochloride according to claim 1 further characterised by the following x-ray powder diffraction pattern expressed in terms of "d" spacings and relative intensities (1) (s=strong, m=medium, w=weak, v=very, d=diffuse) and obtained by the Debye Scherrer method in a 114.6 mm diameter camera by exposure for 12 hours to CoK.sub.a radiation and for 3 hours to CuKa radiation:

3. A pharmaceutical composition in the form of tablets comprising Form 2 ranitidine hydrochloride as defined in claim 1 together with at least one inert pharamceutically acceptable carrier or diluent.

4. A pharmaceutical composition in the form of tablets comprising Form 2 ranitidine hydrochloride as defined in claim 2 together with at least one inert pharmaceutically acceptable carrier or diluent.

5. A pharmaceutical composition in the form of capsules comprising Form 2 ranitidine hydrochloride as defined in claim 1 together with at least one inert pharmaceutically acceptable carrier or diluent.

6. A pharmaceutical composition in the form of capsules comprising Form 2 ranitidine hydrochloride as defined in claim 2 together with at least one inert pharmaceutically acceptable carrier or diluent.

7. A pharmaceutical composition in the form of a powder comprising Form 2 ranitidine hydrochloride as defined in claim 1 together with at least one inert pharmaceutically acceptable carrier or diluent.

8. A pharmaceutical composition in the form of a powder comprising Form 2 ranitidine hydrochloride as defined in claim 2 together with at least one inert pharmaceutically acceptable carrier or diluent.

9. A pharamaceutical composition in the form of lozenges comprising Form 2 ranitidine hydrochloride as defined in claim 1 together with at least one inert pharmaceutically acceptable carrier or diluent.

10. A pharmaceutical composition in the form of lozenges comprising Form 2 ranitidine hydrochloride as defined in claim 2 together with at least one inert pharmaceutically acceptable carrier or diluent.

11. A pharmaceutical composition in the form of suppositories comprising Form 2 ranitidine hydrochloride as defined in claim 1 together with at least one inert pharmaceutically acceptable carrier or diluent.

12. A pharmaceutical composition in the form of suppositories comprising Form 2 ranitidine hydrochloride as defined in claim 2 together with at least one inert pharmaceutically acceptable carrier or diluent.

13. A pharmaceutical composition in the form of retention enemas comprising Form 2 ranitidine hydrochloride as defined in claim 1 together with at least one inert pharmaceutically acceptable carrier or diluent.

14. A pharmaceutical composition in the form of retention enemas comprising Form 2 ranitidine hydrochloride as defined in claim 2 together with at least one inert pharmaceutically acceptable carrier or diluent.

15. A pharmaceutical composition in the form of an ointment comprising Form 2 ranitidine hydrochloride as defined in claim 1 together with at least one inert pharmaceutically acceptable carrier or diluent.

16. A pharmaceutical composition in the form of an ointment comprising Form 2 ranitidine hydrochloride as defined in claim 2 together with at least one inert pharmaceutically acceptable carrier or diluent.

17. A method of treating condition mediated through histamine H.sub.2 -receptors which comprises administering to a patient an effective amount of a compound as claimed in claim 1 to relieve said condition.

18. A method of treating condition mediated through histamine H.sub.2 -receptors which comprises administering to a patient an effective amount of a compound as claimed in claim 2 to relieve said condition.
« Back to Dashboard

For more information try a trial or see the database preview and plans and pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

`abc